Skip to main content

Table 1 Vorinostat trials reported in 2009 and 2010

From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Combination therapy

Type of cancer

Phase

N

Outcome (most relevant findings)

Literature

None

Acute myeloid leukemia

II

37

1 Response (group 3 × 200 mg)

Schäfer et al. (2009)

None

Follicular (FL) and mantle cell lymphoma (MCL)

I

10

40% Response; 2CRu, 1PR (FL); 1CRu (MCL)

Watanabe et al. (2010)

None

Solid tumors

I

18

MTD was not reached

Fujiwara et al. (2009)

None

Advanced prostate cancer

II

27

2SD; all patients off therapy before 6 months

Bradley et al. (2009)

None

Recurrent glioblastoma multiforme

II

52

9 Progression-free after 6 month

Galanis et al. (2009)

Bortezomib

Relapsed and refractory multiple myeloma

I

23

42% Response rate; 3PR

Badros et al. (2009)

Peg-Lip-Doxorubicin, Bortezomib

Relapsed/refractory Multiple Myeloma

I

7

1CR, 1vgPR, 4PR

Voorhees et al. (2009)a

Idarubicin, Cytarabine

Acute myelogenous leukemia

II

45

Response rate 80%; 35CR, 1CRP

Garcia-Manero et al. (2009)a

Lenalidomide, Dexamethasone

Relapsed/refractory multiple myeloma

I

25

Response rate 64%; 1CR, 1nCR, 2vgPR, 8PR, 4MR, 5SD

Siegel et al. (2009)a

Decitabine

Acute myelogenous leukemia/myelodysplastic syndrome

I

MDS n = 11 AML n = 50

MDS: 2CR, 1PR, 1HI, 7SD AML: 7CR, 4CRi, 2PR, 3HI, 26SD

Kirschbaum et al. (2009)a

Rituximab, Ifosphamide, Carboplatin, Etoposide (ICE)

Relapsed/refractory lymphoid malignancies, untreated T-cell/mantle cell lymphoma

I

14

1CR, 2CRu, 9PR, 1SD

Budde et al. (2009)a

pelvic palliative radiotherapy

Gastrointestinal carcinoma

I

16

MTD = 300 mg once daily

Ree et al. (2010)

5-FU, Leucovorin

Metastatic colorectal cancer

I/II

10

No MTD could be established; 2SD; study was closed

Wilson et al. (2010)

Carboplatin, Paclitaxel

Advanced stage NSCLC

II

94

34% Response with Vorinostat vs 12.5% with Placebo

Ramalingam et al. (2010)

Doxorubicin

Solid tumors

I

24

MTD = 800 mg; 2PR (breast, prostate cancer); 2SD (melanoma)

Munster et al. (2009a)

5-FU, Leucovorin, Oxaliplatin

Refractory colorectal cancer

I

21

MTD = 300 mg twice daily

Fakih et al. (2009)

Tamoxifen

Advanced breast cancer

II

29

6 Response; 3SD

Munster et al. (2009c)a

Bortezomib

Refractory solid tumors

I

29

MTD 300 mg BID

Ninan et al. (2009)a

Gemcitabine, Cisplatinum

Advanced NSCLC

I

28

9PR, 8SD

Trédaniel et al. (2009)a

Erlotinib

NSCLC

I

13

6SD

Reguart et al. (2009)a

Docetaxel

Solid tumors

I

12

No response

Schneider et al. (2009)a

  1. aMeeting report abstract